Loading clinical trials...
Loading clinical trials...
A Multi-Center Biologic Assignment Trial Comparing Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients w/Intermediate-2 & High Risk Myelodysplastic Syndrome (BMTCTN1102)
Conditions
Interventions
Allogeneic Hematopoietic Cell Transplant
Hypomethylating Therapy / Best Supportive Care
Locations
37
United States
City of Hope National Medical Center
Duarte, California, United States
Stanford Hospital and Clinics
Stanford, California, United States
University of Florida College of Medicine
Gainesville, Florida, United States
H. Lee Moffitt Cancer Center
Tampa, Florida, United States
Emory University
Atlanta, Georgia, United States
University of Chicago
Chicago, Illinois, United States
Start Date
December 16, 2013
Primary Completion Date
October 5, 2021
Completion Date
October 5, 2021
Last Updated
March 3, 2023
NCT06465953
NCT07081087
NCT03520647
NCT06859424
NCT05589896
NCT04645199
Lead Sponsor
Medical College of Wisconsin
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions